1
|
Hailu S, Hurst C, Cyphers G, Thottunkal S, Harley D, Viney K, Irwin A, Dean J, Nourse C. Prevalence of extra-pulmonary tuberculosis in Africa: A systematic review and meta-analysis. Trop Med Int Health 2024; 29:257-265. [PMID: 38263374 DOI: 10.1111/tmi.13970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2024]
Abstract
OBJECTIVE The burden of extra-pulmonary tuberculosis (EPTB) is not well quantified in TB endemic countries such as those in sub-Saharan Africa. This study aimed to quantify that burden via a systematic review of the prevalence of EPTB in African countries. METHODS Studies were retrieved by searching five databases; 105 studies published between 1990 and 2023 were included. The studies described the prevalence of EPTB among the general population (4 studies), TB patients (68) and patients with other conditions, including HIV (15), meningitis (3), renal failure (3) and other comorbidities, some of which are cancer (12). Due to the low number of studies reporting EPTB in patients with conditions other than TB, the meta-analysis was performed on studies reporting on EPTB among TB patients (68 studies). Meta-analysis was performed on the 68 studies (271,073 participants) using a random-effects model to estimate the pooled prevalence of EPTB. Meta-regression was used to explore possible explanations for heterogeneity according to regions and time periods. RESULTS The pooled prevalence of EPTB among TB patients was 26% (95% CI 23-29%). There was substantial heterogeneity of prevalence for the five African regions. The Eastern region had the highest prevalence of 32% (95% CI 28-37%) and the lowest in Western Africa, 16% (95% CI 10-24%). There was no significant difference in the prevalence of EPTB between the 3 eleven-year time periods. CONCLUSIONS Our systematic review and meta-analysis give insight into the burden of EPTB in Africa. This review could inform clinical and programmatic practices-a higher suspicion index for clinicians and more effort for better services. This could contribute to efforts aiming to end TB, which have historically been focused on PTB.Coordinated efforts that target both EPTB and PTB are needed.
Collapse
Affiliation(s)
- Semira Hailu
- UQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia
| | - Cameron Hurst
- Molly Wardaguga Research Centre, Charles Darwin University, Brisbane, Australia
| | - Griffin Cyphers
- Faculty of Medicine, School of Public Health, The University of Queensland, Brisbane, Australia
| | - Stefan Thottunkal
- ANU College of Health and Medicine, Australian National University, Canberra, Australia
| | - David Harley
- UQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia
| | - Kerri Viney
- ANU College of Health and Medicine, Australian National University, Canberra, Australia
- School of Public Health, University of Sydney, Camperdown, Australia
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
| | - Adam Irwin
- UQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia
- Infection Management and Prevention Service, Queensland Children's Hospital, Brisbane, Australia
| | - Judith Dean
- Faculty of Medicine, School of Public Health, The University of Queensland, Brisbane, Australia
- UQ Poche Centre for Indigenous Health, The University of Queensland, Brisbane, Australia
| | - Clare Nourse
- UQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia
- Infection Management and Prevention Service, Queensland Children's Hospital, Brisbane, Australia
| |
Collapse
|
2
|
Charlie L, Saidi B, Getachew E, Wanjiru CL, Abebe M, Tesfahunei HA, Atim MG, Manyazewal T, Mlera RN. Programmatic challenges in managing multidrug-resistant tuberculosis in Malawi. Int J Mycobacteriol 2021; 10:255-259. [PMID: 34494563 PMCID: PMC8542254 DOI: 10.4103/ijmy.ijmy_47_21] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Background Multidrug-resistant tuberculosis (MDR-TB) is one of the most urgent challenges that Malawi tends to take a firm public health action. A recent increase in multidrug MDR-TB cases, a decrease in treatment success rate, and a double increase of lost-to-follow-up call into question the country's programmatic management of MDR-TB (PMDT). As such, the study aimed at exploring programmatic challenges in managing MDR-TB in Malawi. Methods A comprehensive and nonsystematic search was made in PubMed and Google Scholar using mainly the keywords "MDR-TB" "extensively drug-resistant TB," Malawi. The study reviewed existing guidelines and gray literature and reviewed data obtained from the national TB program (NTP) as well. Results The study found the following challenges affecting PMDT: decrease in funding, partial access to GeneXpert, delay in diagnosis, long treatment duration, lack of adequate personal protective equipment, the long turnaround time of culture results, failure to initiate all diagnosed patients on treatment, absence of alternative second-line medicines, and lack of transport from health facilities to patient homes. Conclusion If the Malawi NTP is to achieve a vision of a "TB-free Malawi," rigorous efforts at all levels must be made, including mobilizing domestic resources for improved MDR-TB program performance. Developing partners should continue providing the much-needed funding to the Malawi government to stand in the wake of the MDR-TB crisis.
Collapse
Affiliation(s)
- Loveness Charlie
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University; KNCV TB Foundation, Challenge TB Project, Blantyre, Malawi
| | - Bibie Saidi
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Blantyre, Malawi; Kibong'oto National Tuberculosis Hospital, Kilimanjaro, Tanzania
| | - Emnet Getachew
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Blantyre, Malawi; Department of Public Health, College of Health Science, Arsi University, Asella, Ethiopia
| | - Cathreen Lydiah Wanjiru
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Blantyre, Malawi
| | - Mekdelawit Abebe
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Blantyre, Malawi; Department of Nursing, Saint Peter Tuberculosis Specialized Hospital, Addis Ababa, Ethiopia
| | - Hanna Amanuel Tesfahunei
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Blantyre, Malawi; Hager Biomedical Research Institute, Asmara, Eritrea
| | - Mary Gorret Atim
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Blantyre, Malawi; Department of Clinical Pharmacy, Soroti Regional Referral Hospital, Soroti, Uganda
| | - Tsegahun Manyazewal
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Blantyre, Malawi
| | - Ronald Nachipo Mlera
- Department of Professional Practice and Conduct, Nurses and Midwives Council of Malawi, Lilongwe, Malawi
| |
Collapse
|